𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Effect of parameter variability on physiologically-based pharmacokinetic model predicted drug concentrations

✍ Scribed by Peter Varkonyi; James V. Bruckner; James M. Gallo

Publisher
John Wiley and Sons
Year
1995
Tongue
English
Weight
446 KB
Volume
84
Category
Article
ISSN
0022-3549

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Prediction of pharmacokinetics prior to
Prediction of pharmacokinetics prior to In Vivo studies. II. Generic physiologically based pharmacokinetic models of drug disposition
✍ Patrick Poulin; Frank-Peter Theil 📂 Article 📅 2002 🏛 John Wiley and Sons 🌐 English ⚖ 179 KB

Many in vitro data on physicochemical properties and specific absorption, distribution, metabolism, and elimination (ADME) processes are already available at early stages of drug discovery. These data about new drug candidates could be integrated/ connected in physiologically based pharmacokinetic (

A priori prediction of tissue:plasma par
A priori prediction of tissue:plasma partition coefficients of drugs to facilitate the use of physiologically-based pharmacokinetic models in drug discovery
✍ Patrick Poulin; Frank-Peter Theil 📂 Article 📅 2000 🏛 John Wiley and Sons 🌐 English ⚖ 374 KB 👁 3 views

The tissue:plasma (P t:p ) partition coefficients (PCs) are important drugspecific input parameters in physiologically based pharmacokinetic (PBPK) models used to estimate the disposition of drugs in biota. Until now the use of PBPK models in early stages of the drug discovery process was not possib

Utility of a physiologically–based pharm
Utility of a physiologically–based pharmacokinetic (PBPK) modeling approach to quantitatively predict a complex drug–drug–disease interaction scenario for rivaroxaban during the drug review process: implications for clinical practice
✍ Joseph A. Grillo; Ping Zhao; Julie Bullock; Brian P. Booth; Min Lu; Kathy Robie- 📂 Article 📅 2012 🏛 John Wiley and Sons 🌐 English ⚖ 535 KB

Background: Rivaroxaban is an oral Factor Xa inhibitor. The primary objective of this communication was to quantitatively predict changes in rivaroxaban exposure when individuals with varying degrees of renal impairment are co-administered with another drug that is both a P-gp and a moderate CYP3A4